Perioperative Therapy for Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study aims to observe and evaluate the efficacy and safety of the perioperative
multidisciplinary therapy that combines the preoperative transarterial
chemoembolization(TACE) and the anti-programmed-death-1 antibody (anti-PD-1) Sintilimab
Injection with or without radiotherapy of vein tumor thrombus followed by postoperative
anti-PD-1 injection in the treatment of technically resectable hepatocellular carcinoma
patients with vein thrombosis.